# Silk Road Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/silk-road-medical

- Industry: Medical Devices & Equipment
- Headquarters: Sunnyvale, US
- Website: www.silkroadmedical.com/
- Total disclosed funding: $89M
- Latest round: Series C (Jul 7, 2017)
- Investors on record: 5

## About

Founded in 2007 and based in California, US, Silk Road Medical, Inc. operates as a developer and manufacturer of a medical device that enables transcarotid vascular access. In June 2024, Boston Scientific Corporation agreed to acquire Silk Road Medical, Inc. from CRG, Janus Henderson Investors, Norwest Venture Partners, Vertical Group, and Warburg Pincus for USD 1.16 billion. The transaction is expected to close in H2 2024. As of 2024, the company is led by its CEO, Chas McKhann.

The company’s primary product is the TCAR® System, which is designed to improve carotid artery disease treatment by combining transcarotid access with reverse flow techniques to optimize stent placement and reduce stroke risk. The TCAR® System delivers safer procedures for patients with carotid artery disease. Silk Road Medical also expands its portfolio with products like the Tapered ENROUTE® Transcarotid Stent System and NPS PLUS, advancing medical technology and improving patient care.

## Funding rounds

- Series C, Jul 7, 2017, $42M — Warburg Pincus, Norwest Venture Partners, CRG, Vertical Group, Janus Henderson Investors
- Series B, Apr 25, 2013, $38M — Warburg Pincus, Vertical Group
- Series B, Apr 7, 2011, $8.2M — Warburg Pincus, Vertical Group
- Series A, Apr 13, 2007, $1M — Vertical Group

## Investors

- Vertical Group (https://capitalatlas.ai/funds/vertical-group) — Series A, Series B, Series C
- Warburg Pincus (https://capitalatlas.ai/funds/warburg-pincus) — Series B, Series C
- Norwest Venture Partners (https://capitalatlas.ai/funds/norwest-venture-partners) — Series C
- CRG — Series C
- Janus Henderson Investors — Series C